Related Experiment Videos
Drospirenone: more cases of thrombosis than with levonorgestrel
Abstract:
As of mid-2013, new data have clarified the level of risk of venous and arterial thrombosis in women using oral contraception containing drospirenone, a progestin derived from spironolactone. Several studies showed a statistically significant, approximately twofold increase in the risk of venous thrombosis in women using oral contraception containing drospirenone, compared with women using second-generation oral contraceptives. Another study on arterial thrombosis showed a statistically significant increase in the number of strokes in women using contraceptives containing drospirenone combined with 30 microgram to 40 microgram of ethinylestradiol per tablet, compared with women not using contraception.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Intrauterine Drug Delivery Systems
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Birth Control Methods
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drug Toxicity: Risk factors